|
S. Douglas. Sheldon is a co-founder and Managing Partner of ESP Equity Partners, LLC (www.espequity.com), a private equity fund with offices in New Jersey, Beijing and Bangkok. Previously, in 2000, Mr. Sheldon co-founded ESP Partners LLC, the predecessor to ESP Pharma, a specialty pharmaceutical company acquired by PDL BioPharma in 2005. He has over 30 years of pharmaceutical and related healthcare experience, both internationally and domestically, including having served as Vice-President of Strategic Partnership Development at Parke-Davis Pharmaceuticals. Doug began his career with Pfizer, Inc. where he served nearly 17 years in senior international finance, marketing, country management, and regional line management assignments in South America and Asia. He left Pfizer in 1991 to form TTMC, Ltd, a venture company focused on healthcare and life sciences businesses in South East Asia. Later, in 1994 he founded the Indochina Healthcare Ltd (IHL) joint venture operations in Thailand, Hong Kong, Vietnam and Myanmar, merging TTMC's hospital products business in orthopedics and urology with the oncology and cardiovascular business of Mayne Pharma (formerly F.H. Faulding, Australia). Today, he continues to actively serve as an Executive Director and Chairman of IHL. Mr. Sheldon, who is also fluent in Spanish, received his B.S. in Chemistry from LeMoyne College and M.B.A. in Finance and Marketing from Syracuse University. | 